Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation. (June 2015)

• Record Type: Journal Article
• Authors: Li, Kangan; Gordon, Andrew C; Zheng, Linfeng; Li, Weiguo; Guo, Yang; Sun, Jing; Zhang, Guixiang; Han, Guohong; Larson, Andrew C; Zhang, Zhuoli
• Is Part Of: Nanomedicine. Volume 10:Number 11(2015)
• Page Start: 1761
• Page End: 1774
• Publication Date: 2015-06
• Subjects: liver tumor -- MRI -- natural killer cell -- portal vein -- rat -- transcatheter delivery; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm.15.24
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: To test the hypothesis that MRI can monitor intraportal vein (IPV) transcatheter delivery of clinically applicable heparin-protamine-ferumoxytol (HPF) nanocomplex-labeled natural killer (NK) cells to liver tumor.Materials & methods: Liver tumor rat models underwent catheterization for IPV infusion of HPF-labeled NK cells (NK-92MI cell line). MRI measurements within tumor and adjacent liver tissues were compared pre- and post-NK cell infusion. Histology studies were used to identify NK cells in the target tumors.Results: For first time, we demonstrated that MRI tracks HPF-labeled NK cells migration within liver following IPV delivery.Conclusion: IPV transcatheter infusion permitted selective delivery of NK cells to liver tissues and MRI allowed tracking NK cell biodistributions within the tumors.